Reply to Comments by Kakkar and Dahiya

Abstract

Get full access to this article

View all access options for this article.

References

Chahine

Karaoui

Mansour

. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis [published online November 1, 2013]. Ann Pharmacother. doi:10.1177/1060028013504087.

Kakkar

Dahiya

. Current issues with the use of bedaquiline [letter]. Ann Pharmacother. 2014;48:666.

Tiberi

De Lorenzo

Centis

. Bedaquiline in MDR-/XDR-TB cases: first experience on compassionate use. Eur Respir J. 2014;43:289-292.

van Halsema

Humphreys

Bonington

. Extensively drug-resistant tuberculosis: early access to bedaquiline for a UK patient. Eur Respir J. 2014;43:292-294.

World Health Organization. The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance. Geneva, Switzerland: World Health Organization; 2013. http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482_eng.pdf. Accessed January 11, 2013.

Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR Recomm Rep. 2013;62(RR-09):1-12.